|
|
|
| Research & Development Status and Future Suggestions of Pharmaceutical Industry in China |
| PU Run1, GUAN Zhen-he1, SU Yue1, GENG Xiang-nan2, AO Yi1 |
1. China National Center for Biotechnology Development, Beijing 100036, China;
2. Institute of Economics of the Chinese Academy of Social Sciences, Beijing 100836, China |
|
|
|
Abstract Accomplished with the development of the worlds' pharmaceutical Industry, a new pattern that most profit is brought by few enterprises or products is established. Compare to the developed countries which have advanced pharmaceutical Industry, ours are huge but weak. Few enterprises are growing gradually while the others are short of R&D investment seriously. According to the situation of R&D and our pharmaceutical industry, we proposed a new viewpoint that helps the production of blockbuster drugs independently in this paper. And detailed recommendations on seizing the opportunity, improving innovation ability, Participating in international competition and nurturing environment for innovation were also given.
|
|
Received: 11 March 2014
Published: 25 July 2014
|
|
|
|
|
|
[1] Garnier J.Rebuilding the R&D engine in big pharma. Harvard Business Review, 2008, 86(5): 68.
[2] 陆国庆, 吴雪钗, 胡婷婷. 恩必普.中国新药杂志, 2006, 7(15): 572-573. Lu G Q, Wu X C, Hu T T. Butylphthalide. Chinese Journal of New Drugs, 2006, 7(15): 572-573.
[3] 李国栋, 周全, 赵长文, 等. 青蒿素类药物的研究现状.中国药学杂志, 1998, 33(7): 385-389. Li G D, Zhou Q, Zhao C W, et al. Research status of artemisinin drugs. Chinese Pharmaceutical Journal, 1998, 33(7): 385-389.
[4] 姚震宇.盘点 2010年五大潜力重磅炸弹. 中国医药工业杂志, 2010, 41(12): 952-956. Yao Z W. Five potential blockbuster drugs in 2010. Chinese Journal of Pharmaceuticals, 2010, 41(12): 952-956.
[5] 付丽红, 徐建国, 尚靖. 新药研究开发中有关问题的思考. 中国药房, 2004, 15(5): 267-268. Fu L H, Xu J G, Shang J. On the problems in research and development of New Drugs. China Pharmacy, 2004, 15(5): 267-268.
[6] 樊志萍, 凌沛学. 医药技术成果转化的瓶颈与对策. 食品与药品, 2011, 13(9): 330-332. Fan Z P, Ling P X. Bottleneck and countermeasures of transformation of medical technological achievements. Food and Drug, 2011, 13(9): 330-332.
[7] DiMasi J A, Hansen R W, Grabowski H G.The price of innovation: new estimates of drug development costs.J Health Econ, 2003, 22(2): 151-186.
[8] 冯国忠, 孟令杰. 国际创新药物研究与产业化开发的特点与趋势. 生物技术产业, 2006(4): 94-97. Meng G Z, Meng L J. Features and trends on research and industrial development of international innovative drugs, Biotechnology & Business, 2006(4): 94-97.
[9] 钟敏. 未来的重磅炸弹级药物. 上海医药, 2006, 27(2): 80-83. Zhong M, Blockbuster drugs in future. Shanghai Medical & Pharmaceutical Journal, 2006, 27(2): 80-83.
[10] Trouiller P, Olliaro P, Torreele E,et al. Drug development for neglected diseases: a deficient market and a public-health policy failure.The Lancet, 2002, 359(9324): 2188-2194.
[11] 安新颖, 冷伏海. 基于结构方程模型的企业自主创新能力研究. 科技进步与对策, 2008, 25(4): 63-66. An X Y, Leng F H. Research on the Independent Innovation Capability of Enterprise Based on SEM. Science & Technology Progress and Policy, 2008, 25(4): 63-66.
[12] Bunnage M E.Getting pharmaceutical R&D back on target.Nature Chemical Biology, 2011, 7(6): 335.
[13] 李野, 游述华, 沈枫. 我国制药企业国际化经营形势分析及策略探讨. 中国药房, 2003, 14(10): 582-584. Li Y, You S H, Shen F. Study of the situation and the strategy of internationized management of Chinese pharmaceutical enterprises. China Pharmacy, 2003, 14(10): 582-584.
[14] 黎慧贞. 中美两国新药申请审评程序的差异. 中药材, 2003, 26(8): 600-602. Li H Z. Differences on new drug application review process between PRC and USA, Journal of Chinese Medicinal Materials, 2003, 26(8): 600-602.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
